Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Calliditas IPO raises $90m to support rare disease pipeline

Calliditas has raised $90m in its IPO to support the development and commercialisation of its lead candidate Nefecon in IgAN, a rare kidney disease. What other rare diseases are Calliditas looking at for both Nefecon and other, possible in-licensed products?

Close
Close
Close

Go Top